The effects of topiramate (TPM) on components of energy balance were tested in male and female rats that were (i) left intact, (ii) castrated or (iii) castrated with replacement therapies consisting of testosterone administration in orchidectomized (OCX) rats and of estradiol or progesterone treatments in ovariectomized (OVX) rats. METHODS: TPM was mixed into the diet and administered at a dose of 60 mg per kg of body weight. Male and female rats were treated for 28 and 35 days, respectively. At the end of the treatment period, variables of energy balance and determinants of lipid and glucose metabolism were assessed. RESULTS: TPM reduced energy and fat gains in both male and female rats either in the absence or in the presence of hormone replacement therapies. In male rats, it also decreased food intake, protein gain and energetic efficiency. In female animals, TPM reduced energetic efficiency while it stimulated lipoprotein lipase activity in brown adipose tissue. TPM also reduced plasma glucose and plasma leptin levels in female rats as well as plasma insulin and liver triglycerides in male animals. As expected, castration and sex hormones also strongly influenced energy balance. In male rats, OCX led to a decrease in energy and protein gains that was blocked by treatment with testosterone. In female rats, OVX caused increases in energy, fat and protein gains that were prevented by treatment with estradiol. CONCLUSION: In female rats, the effects of TPM on fat and energy gains were clearly not influenced by the sex hormone status of the rats. In male animals, there was also no interaction of TPM and the status of sex hormones on energy balance, suggesting that OCX and testosterone minimally interfere with the action of TPM on energy balance. The effects of TPM on energy balance were accounted for by a decrease in energetic efficiency, resulting from an effect exerted by the drug on both energy intake and thermogenesis. The present results also suggest that TPM can enhance insulin sensitivity.
Introduction
Topiramate (TPM) is a structurally novel neurotherapeutic agent synthesized from D-fructose. It contains a sulphamate moiety that is essential for pharmacological activity. 1 TPM is currently indicated for the treatment of epilepsy, and is undergoing development for a wide variety of other indications including obesity, neuropathic pain, bipolar disorder and migraine. TPM has been reported to exert multiple biochemical=pharmacological effects that may determine its broad range of activities including anticonvulsant, analgesic and mood stabilizing properties. No less than five mechanisms of actions of TPM have been identified, including (i) a positive modulatory effect on the activity of GABA at GABA A receptors, 2, 3 (ii) a negative modulatory effect on the activity of glutamate at kainate=AMPA receptors, 4, 5 (iii) a negative modulatory effect on voltage-dependent sodium channels, 6 -10 (iv) a negative modulatory effect on some high-voltage-activated calcium channels, 11 and (v) an inhibitory effect on carbonic anhydrase (CA), particularly CA-LI and CA-IV 12 In contrast to most antiepiletic drugs (AEDs), 13 -15 TPM exerts a negative effect on body weight and energy balance. Data gathered in epileptic patients as well as in rats and mice 13 -17 have clearly shown that TPM can lower body weight and body weight gain. These observations prompted the initiation of studies to address the mechanisms whereby the drug influences energy balance regulation. TPM has now been observed to reduce weight gains in rats and mice 16, 18, 19 (Richard, D and Deshaies, Y, unpublished data). Recent human 20 and animal studies 18, 19 have clearly demonstrated that TPM can significantly retard energy deposition by markedly reducing energetic efficiency. The blunted energy deposition caused by TPM was mainly associated with a retardation in fat deposition. 16, 18, 19 The negative effects of TPM on body weight and energy balance have been reported to be significant in both male and female rats. 16, 18, 19 However, there is evidence that the negative effect of TPM on weight gain is stronger in female than in male rats (Shank, personal communication) . In addition, recent data from this laboratory have shown that the negative effect of TPM on the energy gain of Sprague -Dawley rats was more pronounced in female than in male animals, 19 further raising the possibility that gender and sex hormones could modulate the effects of TPM on energy metabolism. Sex hormones are known to exert strong effects on energy balance 21 -23 and there has been so far no report describing potential effects of these hormones on the action of TPM in the regulation of energy balance. In female rats, the removal of ovaries leads to an increase in energy gain, which is prevented or reversed by estrogens, 21, 23 whereas the removal of testosterone causes a reduction in energy gain due to the lack of testosterone. 22 The present study was therefore undertaken to assess whether sex steroids influence the effects of TPM on energy metabolism in male and female rats.
Materials and methods
Animals, diet and design Male (initial weight 175 -200 g) and female (initial weight 150 -175 g) Wistar rats were purchased from the Canadian Breeding Laboratories (St-Constant, Canada). All rats were cared for and handled in accordance with the Canadian Guide for the Care and Use of Laboratory Animals. Rats were individually housed in stainless cages under controlled temperature (23 AE 1 C) and lighting (07:00 -17:00 light). The animals were allowed unrestricted access to food and water. Throughout the study, rats were given a purified, highcarbohydrate diet, which was composed of (g=l00 g): cornstarch, 31 Male rats were assigned to a three (hormone status: gonadally intact (intact), ochidectomy (OCX), and OCX, testosterone (T)) by two (drug: placebo and TPM) experimental design. The six groups formed were labelled as follows: (i) intact, placebo; (ii) intact, TPM; (iii) OCX, placebo; (iv) OCX, TPM; (v) OCX, T, placebo; (vi) OCX, T, TPM. Female rats were subjected to a four (hormone status: intact, ovariectomy (OVX), OVX, estradiol (E 2 ), and OVX, progesterone (P)) by two (drug: placebo and TPM) experimental design. Eight groups were therefore formed and were identified as follows: (i) intact, placebo; (ii) intact, TPM; (iii) OVX, placebo;(iv) OVX, TPM; (v) OVX, E 2 , placebo; (vi) OVX, E 2 , TPM; (vii) OVX, P, placebo; (viii) OVX, P, TPM.
Surgeries and treatments OCX and OVX were performed under isoflurane anaesthesia according to the procedures described by Waynforth. 24 The total operations were completed within 15 min. The testes were excised following incision of the scrotum and ligation of the spermatic blood vessels and vas deferens. The ovaries were pulled out of the body through two small skin incisions by grasping the periovarian fat, and the junction between the fallopian tube and the uterine horn was sutured and severed in a single cut. Sham-operated (intact) animals were handled in the same way as OCX and OVX animals except that gonads were not excised.
Testosterone, estradiol and progesterone were delivered through silastic implants that were inserted subcutaneously in the dorsal area of the rats. The size of the implants was determined to yield physiological levels of the hormonestestosterone: 3 cm (length of steroid in silastic tubing), 3.2 mm (outer diameter of silastic tubing), and 1.5 mm (inner diameter of silastic tubing); estradiol: cholesterol (1:50, w=w), 0.5 cm (length of diluted steroid in silastic tubing), 3.2 mm (outer diameter of silastic tubing), and 1.5 mm (inner diameter of silastic tubing); progesterone: 2Â0.4 cm (length of steroid in silastic tubing), 3.2 mm (outer diameter of silastic tubing), and 1.5 mm (inner diameter of silastic tubing) 22, 25, 26 The implants were immersed in 0.9% NaC1 at 37 C overnight before their subcutaneous insertion in animals.
TPM was administered at a daily dose of 60 mg per kg of body weight. It was mixed with food. Male and female rats were respectively treated for 28 and 35 days, that is from the surgery to the time of killing.
Blood and tissue collection
At the time of killing (between 13:00 and 15:00), fasted rats (from 07:00 to the time of killing) were anaesthetized with an i.p. injection of 0.4 ml=kg of a ketamine (20 mg=ml):xyml):xylazine (2.5 mg=ml) solution. Blood was harvested immediately thereafter by cardiac puncture, centrifuged (1500 g, 15 min at 4 C), and the separated plasma was stored at 7 70 C until later biochemical measurements. Immediately following the death of the rats, a sample of liver was immediately frozen and stored at 7 70 C until later determination of lipid content. Retroperitoneal and inguinal white adipose tissues (WAT), interscapular brown adipose tissue (BAT) and the soleus muscle were also excised for determination of LPL activity. BAT was cleaned of adhering white fat and muscle tissue. Tissues were weighed, Topiramate, sex hormones and energy balance D Richard et al approximately 50 mg were taken from WAT, BAT and the soleus, and tissue samples were homogenized using all-glass tissue grinders (Kontes, Vineland, NJ, USA). The WAT and BAT samples were homogenized in 1 ml of a solution containing 0.25 M sucrose, 1 mM EDTA, 10 mM Tris-HCL and 12 mM deoxycholate, pH 7.4. The soleus muscle samples were homogenized in 1 ml of a solution containing 1 M ethylene glycol, 50 mM Tris-HCL, 3 mM deoxycholate, 10 IU=ml heparin, and 5% (v=v) aprotinin (Trasylol, Miles Pharmaceuticals, Rexdale, Ontario, Canada), pH 7.4. These homogenizing media were found to yield optimal LPL activities in the individual tissues. Homogenates of muscle tissues were quickly frozen and stored at 7 70 C until measurement of LPL activity. WAT and BAT homogenates were centrifuged at 12 000 g, 4 C for 20 min. The fraction between the upper fat layer and the bottom sediment was removed after tube slicing, diluted with 4 vols of the homogenization solution without deoxycholate, and stored at 7 70 C until later measurement of protein content and LPL activity.
Energy balance and body composition measurements
Throughout the study, body weight and the amount of food ingested were monitored every other day. Food spilled on the absorbent paper was carefully collected, allowed to dry and accounted for in the food intake calculations. Energy intake was calculated by multiplying cumulated intakes of food by the digestible energy (DE) content of the diet. The DE was determined as being 95% of the gross energy density of the diet. This determination was based on previous studies 27, 28 in which the energy content of the faeces was analysed.
At the end of the experimental treatment, carcasses were collected and processed to determine their contents in energy, fat and protein. They were autoclaved at 125 kPa for 15 min to soften hard tissues and homogenized in a volume of water corresponding to twice their weight. The autoclave procedure has been reported not to affect energy yield. 29 The homogenized carcasses were freeze-dried pending the determination of their energy and nitrogen contents. Carcass energy content was determined by adiabatic bomb calorimetry and carcass nitrogen was determined in 250 -300 mg samples of dehydrated carcasses using the Kjeldahl procedure. Carcass protein content was computed by multiplying the carcass nitrogen content by 6.25. The energy as protein was subtracted from total carcass energy in order to determine energy as non-protein matter. As carbohydrate represents a negligible part of carcass total energy, 30 energy from non-protein matter was assumed to be essentially that of fat. Such an assumption tends to be confirmed by studies in which energy, fat and protein were directly determined. 31 Values of 23.5 and 39.3 kJ=g were used for the calculation of the energy content of protein and fat, respectively. 30 Initial energy, fat and protein contents of the carcasses were estimated from the live body weight of rats with reference to a baseline group of rats killed at the beginning of the experimental period. Such estimates allow gains in energy, fat and protein to be determined for the treatment period. The rats (eight for each sex) in the baseline groups were killed at the beginning of the energy balance trial, and the carcass of each animal was analysed for energy. The densities in energy (kJ of energy=g of body weight), protein (g of protein=g of body weight) and fat (g of fat=g of body weight) were then computed and averaged. The average densities were then multiplied by the initial body weight of each rat ascribed to experimental groups. Rats in the initial group were identical in every respect (age, gender) to those of the experimental groups. Apparent energy expenditure was calculated by subtracting the energy gain from DE intake. Gross energetic efficiency was expressed as the ratio of energy gain to DE intake multiplied by 100.
Tissue measurements
After thawing of the frozen liver samples, total lipids were extracted according to the method of Folch et al 32 and solubilized in isopropanol. Cholesterol and triglycerides were quantitated in these lipid extracts as described below for plasma. LPL activity in WAT, BAT and soleus was measured as described earlier. 33 Upon thawing, samples of 100 ml of tissue homogenates prepared as described above were incubated for 1 h at 28 C under gentle agitation with 100 ml a substrate mixture consisting of 0.2 M Tris -HCl buffer, pH 8.6, which contained 10 MBq=l [carboxyl- 14 C]-triolein (Amersham, Oakville, Canada) and 2.52 mM unlabelled triolein emulsified in 50 g=l gum arabic, as well as 20 g=l fatty acid free bovine serum albumin, 10% pig serum as a source of apolipoprotein C-II, and either 0.2 M or 2 M NaC1. Free oleate released by LPL was then separated from intact triolein, 34 mixed with Universol (New England Nuclear, Montréal, Canada) and sample radioactivity was determined in a scintillation counter. LPL activity was calculated by subtracting lipolytic activity determined in a final NaCl concentration of 1 M (non LPL activity) from total lipolytic activity measured in a final NaCl concentration of 0.05 M. Under the present conditions, 1 M NaCl inhibited 82 -91% of total lipolytic activity in all tissue homogenates. LPL activity was expressed as mUnits (1 mU ¼ 1 mmol nonesterified fatty acids released per hour of incubation at 28 C). The interassay coefficient of variation was 4.8% and was determined using bovine skim milk as a standard source of LPL. Protein content of the homogenates was measured by the method of Lowry et al. 35 Plasma determinations Plasma glucose concentrations were measured with the Beckman glucose analyser (Beckman Instruments, Palo Alto, CA, USA). Plasma triglycerides were assayed by an enzymatic method using a reagent kit from Roche Diagnostics (Laval, Quebec, Canada), the triglyceride assay allowed correction for free glycerol. Plasma insulin and leptin were determined by radioimmunoassay using reagent kits from Linco 
Statistical analysis
A 3Â2 factorial analysis of variance (ANOVA) was used to determine the main and interactive effects of 'hormone status' (intact, OCX and OCX þ T) and 'drug' (placebo and TPM) in male rats, whereas a 4Â2 factorial ANOVA was used to determine the main and interactive effects of 'hormone status' (intact, OVX, OVX þ E 2 and OVX þ P) and 'drug' (placebo and TPM) in female animals. When appropriate, a posteriori comparisons were performed using the Bonferoni=Dunn procedure. A simple regression analysis was used to assess the relation between leptin and fat mass.
Results Tables 1 and 2 depict the effects of TPM on energy balance of male and female rats. In male rats (Table 1) , TPM significantly reduced energy intake, energy gain and energetic efficiency. The main effect of 'hormone status' seen on energy intake and energy gain was accounted for by the lower intake and gain of OCX rats compared to intact animals and OCX rats treated with testosterone. In female rats (Table 2) , TPM also significantly reduced energy gain and energetic efficiency, consistent with a reduction in food intake (P ¼ 0.08) and an increase in energy expenditure (P ¼ 0.07). OVX led to significant increases in energy gain and energetic efficiency. Treatment with progesterone did not prevent the effect of OVX on energy balance, whereas treatment with estradiol did. The increase in energetic efficiency induced by OVX was due to an increase in food intake that was not compensated by a proportional elevation in energy expenditure. The effects of TPM on the gains in body weight, fat and protein of male and female rats are presented in Figures 1  and 2 . TPM significantly reduced fat gains in both male and female animals. This effect was more or less consistent with the effects of TPM on body weight gain. In male rats, TPM and OCX led to reductions in protein gain whereas testosterone prevented the effect of OCX. In female animals, OVX enhanced gains in both fat and protein masses whereas estradiol prevented this increase. Treatment with progesterone significantly blocked the effect of OVX on protein gain but only partially prevented the effect of castration on fat gain. ANOVA revealed no 'drug'-by-'hormone status' interaction on any of the variables presented in Figures 1 and 2 . The effects of TPM on whole body fat and protein gain were consistent with the effects of TPM on muscle and fat depot weights (data not shown).
A 'drug'-by-'hormone status' interaction on LPL activity in WAT was observed in male rats (Figure 3 ). The interaction reached the level of statistical significance (P < 0.05) for total LPL activity in inguinal WAT; OCX appeared to prevent the lowering effect of TPM in rats with intact gonads. In addition, OCX per se increased LPL activity in retroperitoneal WAT and testosterone reversed this effect (data not shown). In female rats, TPM increased LPL activity in BAT (Figure 4) . However, the main effect of 'drug' as well as the Topiramate, sex hormones and energy balance D Richard et al interaction effect of 'drug'-by-'hormone status' on LPL activity in either WAT or muscle depots were not significant (data not shown). OVX increased total LPL in parametrial WAT, an effect that was reversed by treatment with estradiol (data not shown). Plasma concentrations of glucose were not affected by TPM in male rats (Table 3 ) but were significantly lowered in female animals (Table 4 ). In contrast, TPM reduced insulinaemia in male rats (Table 3) , whereas it did not alter insulin levels in female animals (Table 4) . TPM strongly reduced liver TG levels in male rats (Table 3) but not in female animals. In addition, OCX very significantly reduced plasma levels of TG below control levels (Table 3 ). This effect was completely abolished following testosterone therapy. Plasma levels of leptin, which were not assessed in male rats, were lower in TPM-treated female rats than in female animals receiving the placebo ( Figure 5 ). TPM even lowered leptin values per gram of body fat, suggesting that the effect of TPM on leptin secretion is not solely dependent on fat levels, which were nonetheless strongly correlated with leptin levels in this study ( Figure 5 ).
Discussion
The present study confirms the ability of TPM to reduce body energy gain and demonstrates that this effect is not dependent on the major sex hormones. TPM has been observed to reduce energy gains in male and female Sprague -Dawley rats, 19 in female lean and obese Zucker mutants, 18 and in male Osborne -Mendel rats. 16 The present results also confirmed the strong influence of sex hormones on energy balance. 21 -23 In male rats, the removal of steroids led to decreases in energy and protein gains that were readily blocked by testosterone. In female rats, the removal of ovaries caused increases in energy, fat and protein gains that were prevented by estradiol. Figure 1 Effects of topiramate (TPM) on body weight, protein and fat gains in control rats, orchidectomized (OCX) rats and OCX rats treated with testosterone (T). Each bar represents the mean of eight rats AE standard error. A 3Â2 factorial ANOVA was used to determine the main and interactive effects of 'hormone (horm.) status' (intact, OCX and OCX þ T) and 'drug' (placebo and TPM) in male animals. Figure 2 Effects of topiramate (TPM) on body weight, protein and fat gains in control rats, ovariectomized (OVX) rats and OVX rats treated with either estradiol (E 2 ) or progesterone (P). Each bar represents the mean of eight rats AE standard error. A 4Â2 factorial ANOVA was used to determine the main and interactive effects of 'hormone (horm.) status' (intact, OVX, OVX þ E 2 and OVX þ P) and 'drug' (placebo and TPM) in female animals.
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In female rats, the effects of TPM on body weight and body energy gains were clearly not influenced by the sex hormone status of the rats. TPM reduced the gains either in presence or in absence of estradiol and progesterone. The reducing effects of TPM on energy gain was primarily accounted for by a decrease in fat mass accretion as reported before. 18 The present results also emphasize the ability of estradiol to prevent the stimulating effect of OVX on protein and fat gains. 21, 23 In male animals, there was also no interaction of TPM and the status of sex hormones on energy balance, suggesting that OCX and testosterone minimally interfere with the action of TPM on energy balance. However, the sex hormone status interacted with the action of TPM on LPL activity in WAT. TPM reduced total LPL activity in the inguinal fat depot of animals with intact gonads, whereas it had no influence on this variable in OCX animals. This finding is consistent with the apparently attenuated effects of TPM on fat gain in OCX rats. The ability of OCX to prevent an expected decline in LPL activity has also been observed following a treadmill running programme (Deshaies, Y and Richard, D, unpublished results). In contrast to what was seen in female animals, the reducing effect of TPM on energy gain in male rats was paralleled by significant reductions in both fat and protein gains. The effect on protein mass seemed not to be due to potential effects of TPM on testosterone secretion as it also occurred in OCX rats. It is noteworthy that male rats did not lose, but rather gained less protein mass compared to untreated rats and therefore were not in a catabolic state. In fact, the action of TPM on protein gain has so far only been reported in growing rats. 19 This action has not been reported in adult humans 20 and is not apparent in adult mice (Richard, D and Deshaies, Y, unpublished results). It is noteworthy that any condition leading to energy shortages in rats appear to cause reductions in lean mass accretion. For instance, treadmill running in male rats 36 and estrogen removal in female animals 23 have been reported to reduce gains in both fat and lean masses in concert.
The reducing effect of TPM on energy gain seen in this study was associated with an appreciable decline in energetic efficiency. In fact, this negative action of TPM represents its most consistent effect in laboratory rodents. 18, 19 In female lean Zucker animals as well as in female Sprague -Dawley rats, TPM has been shown to decrease energy gain without reducing energy intake. In these rats, a significant increase in Figure 3 Effects of topiramate (TPM) on lipoprotein lipase activity (LPL) activity in inguinal white adipose tissue of control rats, orchidectomized (OCX) rats and OCX rats treated with testosterone (T). Each bar represents the mean of 6 -8 rats AE the standard error. A 3Â2 factorial ANOVA was used to determine the main and interactive effects of 'hormone status' (intact, OCX and OCX þ T) and 'drug' (placebo and TPM) in male animals. A posteriori comparisons were performed using the Bonferoni=Dunn procedure.
Topiramate, sex hormones and energy balance D Richard et al energy expenditure was noticed. A stimulating effect of TPM on energy expenditure is in consonance with the stimulating impact of the drug on BAT LPL seen in this study and reported previously. 19 An increase in BAT LPL activity has been associated with a stimulation of BAT thermogenesis, 37 which represents a sympathetically mediated process capable of dissipating large amounts of energy in small mammals. 38, 39 TPM has also been observed to activate LPL in skeletal and cardiac muscles, 19 suggesting that these tissues could also participate in the effects of TPM on energy expenditure. Importantly, TPM has been reported not to decrease the digestibility of food. 19, 20 The results of the present study also demonstrate the ability of TPM to alter plasma levels of insulin, glucose and leptin as well as plasma and liver levels of triglycerides. TPM decreased insulin levels in male rats without changing glucose levels. The reduction in insulinaemia, which has also been previously detected in female obese Zucker rats, 18 suggests that TPM increases insulin sensitivity. A recent study has also demonstrated that TPM can improve glucose Figure 4 Effects of topiramate (TPM) on lipoprotein activity (LPL) activity in interscapular brown adipose tissue of control rats ovariectomized (OVX) rats and OVX rats treated with either estradiol (E 2 ) or progesterone (P). Each bar represents the mean of 6 -8 rats AE the standard error. A 4Â2 factorial ANOVA was used to determine the main and interactive effects of 'hormone status' (intact, OVX, OVX þ E 2 and OVX þ P) and 'drug' (placebo and TPM) in female animals. 20 Interestingly, studies that have so far reported reductions in insulinemia following TPM have also reported reductions in food intake, 18, 20 which may indicate that the lowering action of TPM on insulinaemia is caused by a concomitant reduction in food intake induced by the drug. In the absence of hypoinsulinaemia and hypophagia, TPM has nonetheless proved capable of lowering glucose levels. In fact, a significant decrease in blood glucose, comparable to that observed in female Sprague -Dawley rats fed a stock diet (Richard, D and Deshaies, Y, unpublished data), was seen among all female groups in this study. This finding further supports the hypothesis that TPM can enhance insulin sensitivity. In this study, TPM did not significantly reduce plasma levels of TG in contrast to previous investigations. 19, 20 On the other hand, TPM markedly lowered liver TG content in male rats. Finally, marked reductions in leptin levels were seen in female rats. The decrease in leptin levels followed that of fat mass, although a significant effect of TPM on leptin levels persisted even when leptin levels were expressed per unit of fat mass. This reduction in leptin could represent an adaptation to limit further fat loss in TPM-treated rats as leptin is capable of anorectic and thermogenic actions.
Mechanistically, the basis for the effects of TPM on energy balance as well as on glucose and lipid metabolism is not known. In fact, the description of the mechanisms whereby TPM acts on energy metabolism remains a very complex and challenging issue because of the heterogeneous biochemical=pharmacological actions of the drug. Assuming a central action of TPM on the GABA system, one would predict a stimulating effect of TPM on body fat gain comparable to that led to by other AEDs. Indeed, drugs such as valproate and benzodiazepines, which enhance the activity of the GABAa receptor, and vigabatrin, which inhibits the breakdown of GABA, have been reported to promote weight gain in clinical trials. 13 -15 However, TPM has clear negative effects on energetic efficiency, which may suggest that the stimulating action of TPM on the GABA system is not predominant with regard to energy balance. There is recent evidence to suggest that AEDs which inhibit the activity of glutamatergic receptors could promote weight loss.
14 It may also be that TPM does not exert its metabolic effects through a direct action on the brain centers but rather via peripheral mechanisms.
In summary, the present study demonstrates the ability of TPM to reduce energy and fat gains in male and female rats. In female rats, the effects of TPM on fat and energy gains were clearly not influenced by the sex hormone status of the rats. In male animals, there was also an absence of interaction of TPM and the status of sex hormones on energy balance, suggesting that OCX and testosterone minimally interfere with the action of TPM on energy balance. The effects of TPM on energy balance were accounted for by a decrease in energetic efficiency, resulting from actions exerted by the drug on both energy intake and thermogenesis. Overall, TPM effects suggest that peripheral Table 4 Effects of topiramate (TPM) on plasma levels of insulin and triglycerides (TG) and on liver contents of TG in control rats (n ¼ 
